Abstract:Abstract Background We aimed to investigate response and prognostic factors in patients with human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (mCRC) and compare the curative effect on patients who received different therapy regimens (including chemotherapy and chemotherapy combined with targeted drugs). Methods We retrospectively analyzed all HER2 positive mCRC patients treated at Peking University Cancer Hospital between September 2011 and February 2021. We divided 63 HER2 positive mCRC into group A and group B according to the use of trastuzumab or not. Besides, we assigned four subgroups according to the first-line therapies of KRAS/NRAS/BRAF WT patients. The Kaplan–Meier estimator was used to calculate PFS and OS. Univariable analysis and Cox proportional hazards models were used to analyze the association between clinicopathological features and survival outcomes. Results Among 63 patients, 54 (85.7%) were KRAS/NRAS/BRAF wild-type (WT). Univariate analysis showed that the male sex, primary lesions in the right colon, simultaneous metastasis, and unresectable primary lesions were significant risk factors for poor survival of HER2 positive mCRC ( P < 0.05). Using Cox proportional hazards models, we found that the two factors of gender and resection of primary lesions were independent prognostic factors (P < 0.05). The median PFS and median OS of HER2-positive patients with mCRC who received first-line treatment were 8.4 months [95% confidence interval (CI): 5.0–11.7] and 48.2 months (95% CI: 23.5–72.8), respectively. The log-rank test revealed a significant difference in median OS survival between group A and group B (χ 2 = 5.852, P = 0.016), and the two groups were divided according to the use or absence of trastuzumab treatment. In KRAS/NRAS/BRAF WT patients, there was a significant difference in median PFS and median OS between the fourth group patients (chemotherapy plus trastuzumab) and each of the other three groups ( P < 0.05). Conclusions The two factors of gender and resection for primary lesion may be independent prognostic factors of advanced HER2 positive colorectal cancer patients. For patients with HER2-positive mCRC, patients in the chemotherapy combined with trastuzumab group have better efficacy than those without trastuzumab.

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer

HER2 targeted therapy in colorectal Cancer: Current landscape and future directions

Heterogeneity in Primary Colorectal Cancer and Its Corresponding Metastases: a Potential Reason of EGFR-targeted Therapy Failure?

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

Clinicopathologic features and treatment advances in cancers with HER2 alterations

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer

Evolving Perspectives in Clinical Landscape and Molecular Characteristics of HER2-Low Breast Cancer and Beyond

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

HER2 Overexpression and Amplification in Patients with Colorectal Cancer: a Large-Scale Retrospective Study in Chinese Population.

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

HER2: An emerging target in colorectal cancer

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy

Molecular Network of Colorectal Cancer and Current Therapeutic Options